Vital Therapies (NSDQ:VTL) said today that it inked a deal to swap shares with Germany-based Immunic, transitioning its efforts to focus on Immunic’s pipeline of drugs for chronic inflammatory and autoimmune diseases.
Once the deal is closed, Vital Therapies plans to operate under the name Immunic and trade on the Nasdaq market.
Get the full story at our sister site, Drug Delivery Business News.
The post Vital Therapies pulls the trigger on Immunic share swap appeared first on MassDevice.